Recent consensus among healthcare professionals endorses the inclusion of GLP-1 receptor agonists and dual GIP/GLP-1 agonists, such as tirzepatide, in treatment guidelines, emphasizing their efficacy in glycemic control and weight management despite mild gastrointestinal side effects. Clinicians acknowledge concerns regarding severe hypoglycemia in insulinoma patients and muscle-related issues tied to semaglutide, yet stress that these events are rare and manageable. Ongoing monitoring and real-world surveillance will play essential roles in ensuring patient safety and optimizing therapeutic strategies.
Title not available for this citation.
“To our knowledge, this is the first case of HNF4A MODY to be treated with oral semaglutide alone.”
Title not available for this citation.
“Nine months after starting semaglutide and on monotherapy with semaglutide 7 mg daily, hemoglobin A1c was 5.7%.”
Title not available for this citation.
“Oral glucagon-like peptide receptor-1 receptor agonists may be used to treat HNF4A MODY as an independent or adjunctive therapy to sulfonylureas.”
Title not available for this citation.
“Pharmacological progress in obesity: tirzepatide's rising advantage over semaglutide.”
Title not available for this citation.
“This case suggests that the use of tirzepatide can provoke severe hypoglycemia episodes in patients with insulinoma.”
Title not available for this citation.
“and highlights the importance of including insulinoma as a differential diagnosis for hypoglycemia in patients taking incretin-based therapy.”
Title not available for this citation.
“Several studies suggest a dose-response relationship, with greater MASLD severity corresponding to higher risks of complications.”
Title not available for this citation.
“Tirzepatide use was associated with a significantly lower risk of POAG (RR 0.50, 95% CI 0.34-0.74) compared to selective GLP-1 RAs.”
Title not available for this citation.
“Tirzepatide use was associated with a significantly lower risk of OHTN (RR 0.59, 95% CI 0.40-0.88) compared to selective GLP-1 RAs.”
Title not available for this citation.
“Tirzepatide use was associated with a significantly lower need for glaucoma treatment (RR 0.54, 95% CI 0.45-0.64) compared to selective GLP-1 RAs.”
Title not available for this citation.
“Obesity is a chronic, relapsing metabolic disorder driven by complex genetic and environmental factors, leading to an imbalance in energy regulation.”
Title not available for this citation.
“The agents show enhanced pharmacokinetics, synergy with GLP-1 receptor agonist, and favorable impact on weight regulation and metabolic plasticity.”